EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic heterogeneity of Ki67 in non‐small cell lung cancer: A comprehensive reappraisal on immunohistochemistry and transcriptional data

Yujing Yang, Xinye Shao, Zhi Li, Lingyun Zhang, Bowen Yang, Bo Jin, Xuejun Hu, Xiujuan Qu, Xiaofang Che, Yunpeng Liu iD

Journal of Cellular and Molecular Medicine · 2024

DOI: 10.1111/jcmm.18521 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Yujing Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Ki-67 Antigen, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunohistochemistry. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Technological Special Project of Liaoning Province of China, China Medical University High-level Talent Introduction Support Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the present study, the debatable prognostic value of Ki67 in patients with non‐small cell lung cancer (NSCLC) was attributed to the heterogeneity between lung adenocarcinoma (LUAD) and lung squamous carcinoma (LUSC). Based on meta‐analyses of 29 studies, a retrospective immunohistochemical cohort of 1479 patients from our center, eight transcriptional datasets and a single‐cell datasets with 40 patients, we found that high Ki67 expression suggests a poor outcome in LUAD, but conversely, low Ki67 expression indicates worse prognosis in LUSC. Furthermore, low proliferation in LUSC is associated with higher metastatic capacity, which is related to the stronger epithelial‐mesenchymal transition potential, immunosuppressive microenvironment and angiogenesis. Finally, nomogram model incorporating clinical risk factors and Ki67 expression outperformed the basic clinical model for the accurate prognostic prediction of LUSC. With the largest prognostic assessment of Ki67 from protein to mRNA level, our study highlights that Ki67 also has an important prognostic value in NSCLC, but separate evaluation of LUAD and LUSC is necessary to provide more valuable information for clinical decision‐making in NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ki-67 AntigenCarcinoma, Non-Small-Cell LungLung NeoplasmsImmunohistochemistryHumansPrognosisFemaleMaleBiomarkers, TumorGene Expression Regulation, NeoplasticMiddle AgedAgedNomogramsTumor MicroenvironmentCarcinoma, Squamous CellEpithelial-Mesenchymal TransitionRetrospective Studies

Stichwörter der Autor:innen

Ki67non‐small cell lung cancerprognosistumour microenvironmenttumour proliferation

Substanzen

Ki-67 AntigenBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
  • Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
  • Clinical Cancer Research Center of Shenyang, The First Hospital of China Medical University, Shenyang, China.
  • Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Department of Respiratory and Infectious Disease of Geriatrics, The First Hospital of China Medical University, Shenyang, China.

ORCID-Profile: Yunpeng Liu

Förderung

  • National Natural Science Foundation of China
  • Technological Special Project of Liaoning Province of China
  • China Medical University High-level Talent Introduction Support Project
  • Key Research and Development Program of Liaoning Province

Zitieren

APA

Yang, Y., Shao, X., Li, Z., Zhang, L., Yang, B., Jin, B., Hu, X., Qu, X., Che, X., & Liu, Y. (2024). Prognostic heterogeneity of Ki67 in non‐small cell lung cancer: A comprehensive reappraisal on immunohistochemistry and transcriptional data. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18521

Vancouver

Yang Y, Shao X, Li Z, Zhang L, Yang B, Jin B, et al. Prognostic heterogeneity of Ki67 in non‐small cell lung cancer: A comprehensive reappraisal on immunohistochemistry and transcriptional data. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18521

BibTeX
@article{Yang2024,
  author = {Yang, Yujing and Shao, Xinye and Li, Zhi and Zhang, Lingyun and Yang, Bowen and Jin, Bo and Hu, Xuejun and Qu, Xiujuan and Che, Xiaofang and Liu, Yunpeng},
  title = {Prognostic heterogeneity of Ki67 in non‐small cell lung cancer: A comprehensive reappraisal on immunohistochemistry and transcriptional data},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2024},
  doi = {10.1111/jcmm.18521}
}
Kostenlos starten →